A Randomized, Double-blind, Parallel-group, 26-week Study Comparing the Efficacy and Safety of Indacaterol (Onbrez® Breezhaler® 150 μg o.d.) With Salmeterol/Fluticasone Propionate (Seretide® Accuhaler® 50 μg/500 μg b.i.d.) in Patients With Moderate Chronic Obstructive Pulmonary Disease

Trial Profile

A Randomized, Double-blind, Parallel-group, 26-week Study Comparing the Efficacy and Safety of Indacaterol (Onbrez® Breezhaler® 150 μg o.d.) With Salmeterol/Fluticasone Propionate (Seretide® Accuhaler® 50 μg/500 μg b.i.d.) in Patients With Moderate Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Indacaterol (Primary) ; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms INSTEAD
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 30 Oct 2014 Results published in the European Respiratory Journal.
    • 30 Oct 2014 Status changed from active, no longer recruiting to completed according to the Results published in the European Respiratory Journal
    • 25 Apr 2014 Top-line results reported in a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top